{ "schemaVersion": 1, "organisationId": "O-a861bac602ff44ea834a0a14ca1477d6", "slug": "ashland-inc", "name": "ASHLAND INC.", "updatedAt": "2026-10-02T11:24:16.803158Z", "sections": [ { "type": "OVERVIEW", "text": "Ashland Inc. is a global specialty ingredients and additives company serving consumer and industrial markets. Its FY2025 reportable segments were Life Sciences, Personal Care, Specialty Additives and Intermediates; its products include ingredients and functional materials used in applications such as medicines and personal-care products. [P2179846][T10448544] The company states its purpose is “to responsibly solve for a better world.” [https://www.ashland.com/about/careers/ashlands-purpose-and-values]\n\nAshland reported FY2025 sales of $1.824 billion and approximately 2,900 employees. [P95446803][https://www.ashland.com/about/about-ashland] Its sales span North America, Europe, Asia Pacific, and Latin America and other markets, and the company says it serves customers in more than 100 countries. [T16530877][https://www.ashland.com/about/about-ashland]\n[P2179846][T10448544][https://www.ashland.com/about/careers/ashlands-purpose-and-values][P95446803][https://www.ashland.com/about/about-ashland][T16530877][https://www.ashland.com/about/careers/ashlands-purpose-and-values][https://www.ashland.com/about/about-ashland]", "updatedAt": "2026-10-02T11:24:16.803158Z" }, { "type": "PRODUCTS", "text": "Ashland’s Life Sciences products include pharmaceutical and nutrition excipients and tablet-coating systems. They support tablet binding, super-disintegration, sustained release, drug solubilization, and immediate-, delayed- and sustained-release coatings; nutrition ingredients provide functions such as thickening, texture control, thermal gelation, water binding and stabilization. Named products include Benecel™ methylcellulose/hypromellose and Klucel™ hydroxypropylcellulose, used in pharmaceutical formulations and, for Benecel, in food applications. [P23175334][https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/benecel-methylcellulose-and-hypromellose][https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/klucel-hydroxypropylcellulose] In fiscal 2025, cellulosics represented 43% of Life Sciences sales and 39% of consolidated sales; polyvinylpyrrolidones (PVP) represented 42% and 25%, respectively. [T4551084]\n\nPersonal Care products include ingredients for skin, sun, oral and hair care, as well as household solutions. The portfolio includes microbial protectants and preservatives, rheology modifiers, surface-wetting agents, encapsulates and specialty polymers. Sensiva™ products, for example, provide multifunctional antimicrobial and deodorizing or skin-feel functions, depending on grade. [P35925885][https://www.ashland.com/industries/personal-and-home-care/skin-and-sun-care/sensiva-sc-80-multifunctional] Specialty Additives include natural- and synthetic-origin organo- and water-soluble polymers, such as derivatized cellulose and vinyl-pyrrolidone polymers, used as formulation ingredients and processing aids. Examples include Natrosol™ hydroxyethylcellulose and Aquaflow™ associative thickeners for waterborne paints, and Aqualon™ ethylcellulose for industrial coatings. [P42856628][https://www.ashland.com/industries/paints-and-coatings/architectural-paints/natrosol-b-hydroxyethylcellulose][https://www.ashland.com/industries/paints-and-coatings/architectural-paints/aquaflow-nonionic-synthetic-associative-thickeners][https://www.ashland.com/industries/paints-and-coatings/specialty-and-industrial-coatings/aqualon-ethylcellulose]\n\nAshland’s Intermediates products include 1,4-butanediol (BDO), tetrahydrofuran (THF), N-methyl-pyrrolidone (NMP) and gamma-butyrolactone (GBL/BLO); BDO is a precursor to derivatives including polyesters, urethanes, THF and GBL. [https://www.ashland.com/about/business-units/intermediates][https://www.ashland.com/industries/performance-specialties/intermediates/bdo--1-4-butanediol]\n[P23175334][T4551084][P35925885][P42856628][https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/benecel-methylcellulose-and-hypromellose][https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/klucel-hydroxypropylcellulose][https://www.ashland.com/industries/personal-and-home-care/skin-and-sun-care/sensiva-sc-80-multifunctional][https://www.ashland.com/industries/paints-and-coatings/architectural-paints/natrosol-b-hydroxyethylcellulose][https://www.ashland.com/industries/paints-and-coatings/architectural-paints/aquaflow-nonionic-synthetic-associative-thickeners][https://www.ashland.com/industries/paints-and-coatings/specialty-and-industrial-coatings/aqualon-ethylcellulose][https://www.ashland.com/about/business-units/intermediates][https://www.ashland.com/industries/performance-specialties/intermediates/bdo--1-4-butanediol]", "updatedAt": "2026-10-02T11:24:16.803158Z" }, { "type": "GEOGRAPHY", "text": "Ashland’s FY2025 segment sales by geography totaled $1.866 billion before intersegment eliminations: Europe, Middle East and Africa $663 million (about 35.5%); North America—defined as the United States and Canada—$539 million (28.9%); Asia Pacific $477 million (25.6%); and Latin America and other $187 million (10.0%). These are shares of the geographic segment-sales total, not consolidated reported sales. [P78989943][P2527484][T8854885]\n\nAshland’s identified manufacturing locations include Calvert City, Kentucky; Freetown, Massachusetts; and Hopewell, Virginia, in the United States. In July 2025, the company announced plans to close production at Parlin and Chatham, New Jersey, transferring production to Hopewell and Freetown, respectively. Its named European sites include Zwijndrecht, Netherlands; Alizay, France; and Doel, Belgium; it has also reported a pharmaceutical manufacturing plant expansion in Cabreúva, Brazil. [https://www.ashland.com/industries/personal-and-home-care/ashlands-domestic-manufacturing][https://investor.ashland.com/news-releases/news-release-details/ashland-advances-strategic-60mm-network-optimization][https://www.ashland.com/industries/personal-and-home-care/regional-capabilities-and-service][https://www.ashland.com/industries/pharmaceutical/cabreuva-plant-opening]\n[P78989943][P2527484][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][T8854885][https://www.ashland.com/industries/personal-and-home-care/ashlands-domestic-manufacturing][https://investor.ashland.com/news-releases/news-release-details/ashland-advances-strategic-60mm-network-optimization][https://www.ashland.com/industries/personal-and-home-care/regional-capabilities-and-service][https://www.ashland.com/industries/pharmaceutical/cabreuva-plant-opening]", "updatedAt": "2026-10-02T11:24:16.803158Z" }, { "type": "SEGMENTS", "text": "For FY2025, Ashland reported four business segments. Life Sciences focuses on pharmaceutical, nutrition, agricultural chemical, diagnostic-film and fine-chemical markets, including pharmaceutical excipients and nutrition ingredients; it reported $641 million in sales, about 34.4% of segment sales. [P12357039][T10448544] Personal Care supplies biofunctionals and microbial protectants for skin, sun, oral and hair care, and household applications; sales were $577 million, or about 30.9%. [P35925885][T10448544]\n\nSpecialty Additives provides rheology and performance additives for coatings, construction, energy, automotive and industrial markets; sales were $511 million, or about 27.4%. [P47785786][T10448544] Intermediates produces 1,4-butanediol and derivatives, including n-methylpyrrolidone, for uses such as engineering polymers, polyurethanes and specialty-process solvents; sales were $137 million, or about 7.3%. [P92187128][T10448544] Percentages use the $1,866 million sum of segment sales before $42 million of intersegment eliminations; consolidated sales were $1,824 million. [T10448544]\n[P12357039][T10448544][P35925885][T10448544][P47785786][T10448544][P92187128][T10448544][T10448544][T10448544]", "updatedAt": "2026-10-02T11:24:16.803158Z" }, { "type": "HISTORY", "text": "Ashland was founded in Kentucky in 1924 as Ashland Refining Company. In 1936 it consolidated with Swiss Oil to form Ashland Oil & Refining Company, and its shares began trading on the New York Stock Exchange in 1950. [https://www.ashland.com/about/history] In the late 1990s and early 2000s, Ashland moved away from refining and marketing and toward specialty chemicals. Key steps included acquiring Hercules in 2008 and International Specialty Products in 2011, and selling its distribution business in 2011 and Water Technologies business in 2014. [https://www.ashland.com/about/history] [https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-isp-acquisition] [https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-sale-ashland-water-technologies-clayton]\n\nIn 2016, Ashland Global Holdings Inc. became the public parent company following a corporate reorganization; in 2017, Ashland acquired Pharmachem and completed the separation of Valvoline as an independent public company. [P94783752] [P72228304] [P70292229] [https://investor.ashland.com/news-releases/news-release-details/ashland-announces-completion-final-separation-valvoline-inc] In 2019, Guillermo Novo succeeded William A. Wulfsohn as chairman and CEO. [https://investor.ashland.com/news-releases/news-release-details/ashland-announces-ceo-transition] Ashland continued to narrow its portfolio, selling its Performance Adhesives business in 2022, its nutraceuticals business in 2024, and its Avoca business in 2025. [https://www.sec.gov/Archives/edgar/data/1674862/000095017022025539/R10.htm] [P144459497] [https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-nutraceuticals-business] [https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-avoca-business-mane]\n[P94783752][P72228304][P70292229][P144459497][https://www.ashland.com/about/history][https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-isp-acquisition][https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-sale-ashland-water-technologies-clayton][https://investor.ashland.com/news-releases/news-release-details/ashland-announces-completion-final-separation-valvoline-inc][https://investor.ashland.com/news-releases/news-release-details/ashland-announces-ceo-transition][https://www.sec.gov/Archives/edgar/data/1674862/000095017022025539/R10.htm][https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-nutraceuticals-business][https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-avoca-business-mane]", "updatedAt": "2026-10-02T11:24:16.803158Z" } ], "sources": [ { "id": "P2179846", "href": "https://app.finbar.com/go?id=P2179846", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "T10448544", "href": "https://app.finbar.com/go?id=T10448544", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/about/careers/ashlands-purpose-and-values", "href": "https://www.ashland.com/about/careers/ashlands-purpose-and-values", "label": "www.ashland.com" }, { "id": "P95446803", "href": "https://app.finbar.com/go?id=P95446803", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/about/about-ashland", "href": "https://www.ashland.com/about/about-ashland", "label": "www.ashland.com" }, { "id": "T16530877", "href": "https://app.finbar.com/go?id=T16530877", "label": "ASHLAND INC. — Full financial report (2026 Q 3)", "documentId": "D-6e18a78aedc34dbeb2b809ab400d40b6" }, { "id": "P23175334", "href": "https://app.finbar.com/go?id=P23175334", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/benecel-methylcellulose-and-hypromellose", "href": "https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/benecel-methylcellulose-and-hypromellose", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/klucel-hydroxypropylcellulose", "href": "https://www.ashland.com/industries/pharmaceutical/oral-solid-dose/klucel-hydroxypropylcellulose", "label": "www.ashland.com" }, { "id": "T4551084", "href": "https://app.finbar.com/go?id=T4551084", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "P35925885", "href": "https://app.finbar.com/go?id=P35925885", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/industries/personal-and-home-care/skin-and-sun-care/sensiva-sc-80-multifunctional", "href": "https://www.ashland.com/industries/personal-and-home-care/skin-and-sun-care/sensiva-sc-80-multifunctional", "label": "www.ashland.com" }, { "id": "P42856628", "href": "https://app.finbar.com/go?id=P42856628", "label": "ASHLAND INC. — Full financial report (2024 Y)", "documentId": "D-8cb06143182e4acb907d310bc834e1a4" }, { "id": "https://www.ashland.com/industries/paints-and-coatings/architectural-paints/natrosol-b-hydroxyethylcellulose", "href": "https://www.ashland.com/industries/paints-and-coatings/architectural-paints/natrosol-b-hydroxyethylcellulose", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/industries/paints-and-coatings/architectural-paints/aquaflow-nonionic-synthetic-associative-thickeners", "href": "https://www.ashland.com/industries/paints-and-coatings/architectural-paints/aquaflow-nonionic-synthetic-associative-thickeners", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/industries/paints-and-coatings/specialty-and-industrial-coatings/aqualon-ethylcellulose", "href": "https://www.ashland.com/industries/paints-and-coatings/specialty-and-industrial-coatings/aqualon-ethylcellulose", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/about/business-units/intermediates", "href": "https://www.ashland.com/about/business-units/intermediates", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/industries/performance-specialties/intermediates/bdo--1-4-butanediol", "href": "https://www.ashland.com/industries/performance-specialties/intermediates/bdo--1-4-butanediol", "label": "www.ashland.com" }, { "id": "P78989943", "href": "https://app.finbar.com/go?id=P78989943", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "P2527484", "href": "https://app.finbar.com/go?id=P2527484", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "T8854885", "href": "https://app.finbar.com/go?id=T8854885", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/industries/personal-and-home-care/ashlands-domestic-manufacturing", "href": "https://www.ashland.com/industries/personal-and-home-care/ashlands-domestic-manufacturing", "label": "www.ashland.com" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-advances-strategic-60mm-network-optimization", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-advances-strategic-60mm-network-optimization", "label": "investor.ashland.com" }, { "id": "https://www.ashland.com/industries/personal-and-home-care/regional-capabilities-and-service", "href": "https://www.ashland.com/industries/personal-and-home-care/regional-capabilities-and-service", "label": "www.ashland.com" }, { "id": "https://www.ashland.com/industries/pharmaceutical/cabreuva-plant-opening", "href": "https://www.ashland.com/industries/pharmaceutical/cabreuva-plant-opening", "label": "www.ashland.com" }, { "id": "P12357039", "href": "https://app.finbar.com/go?id=P12357039", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "P47785786", "href": "https://app.finbar.com/go?id=P47785786", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "P92187128", "href": "https://app.finbar.com/go?id=P92187128", "label": "ASHLAND INC. — Full financial report (2025 Y)", "documentId": "D-a52f5f26955b46718d941c5325ea9ff0" }, { "id": "https://www.ashland.com/about/history", "href": "https://www.ashland.com/about/history", "label": "www.ashland.com" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-isp-acquisition", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-isp-acquisition", "label": "investor.ashland.com" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-sale-ashland-water-technologies-clayton", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-inc-completes-sale-ashland-water-technologies-clayton", "label": "investor.ashland.com" }, { "id": "P94783752", "href": "https://app.finbar.com/go?id=P94783752", "label": "ASHLAND INC. — Full financial report (2017 Y)", "documentId": "D-b544f837e0f3445086d323c41d8631f9" }, { "id": "P72228304", "href": "https://app.finbar.com/go?id=P72228304", "label": "ASHLAND INC. — Full financial report (2017 Y)", "documentId": "D-b544f837e0f3445086d323c41d8631f9" }, { "id": "P70292229", "href": "https://app.finbar.com/go?id=P70292229", "label": "ASHLAND INC. — Full financial report (2017 Y)", "documentId": "D-b544f837e0f3445086d323c41d8631f9" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-announces-completion-final-separation-valvoline-inc", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-announces-completion-final-separation-valvoline-inc", "label": "investor.ashland.com" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-announces-ceo-transition", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-announces-ceo-transition", "label": "investor.ashland.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1674862/000095017022025539/R10.htm", "href": "https://www.sec.gov/Archives/edgar/data/1674862/000095017022025539/R10.htm", "label": "www.sec.gov" }, { "id": "P144459497", "href": "https://app.finbar.com/go?id=P144459497", "label": "ASHLAND INC. — Full financial report (2026 Q 3)", "documentId": "D-6e18a78aedc34dbeb2b809ab400d40b6" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-nutraceuticals-business", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-nutraceuticals-business", "label": "investor.ashland.com" }, { "id": "https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-avoca-business-mane", "href": "https://investor.ashland.com/news-releases/news-release-details/ashland-completes-sale-avoca-business-mane", "label": "investor.ashland.com" } ] }